Cambridge-based Sage Therapeutics has announced a sweeping layoff of 338 employees—almost its entire workforce—as it prepares to be acquired by Supernus Pharmaceuticals in a deal valued at up to $795 million. The move marks a dramatic turning point for the once-promising biotech firm, reflecting broader upheaval and uncertainty within the biotechnology sector, especially as funding tightens and major product bets face heightened regulatory and commercial risk.

Massive Layoffs Follows Supernus Takeover

According to state regulatory filings, Sage Therapeutics will eliminate 338 positions effective August 22, 2025. Just a few months prior, Sage reported employing 353 full-time staff, with a robust research and development team comprising over a third of its workforce. The job cuts come swiftly—less than two weeks after Sage confirmed its planned acquisition by Maryland’s Supernus Pharmaceuticals, a specialist in therapies targeting central nervous system (CNS) disorders.

Under the terms of the deal, which was announced in mid-June, Supernus will pay up to $795 million for Sage, signaling a consolidation trend as mid-sized pharmaceutical companies seek next-generation therapies amid an increasingly competitive landscape. The acquisition follows a strategic realignment in August 2023, when Sage laid off roughly 40% of its workforce after a major drug setback.

What’s Behind Sage’s Dramatic Downturn?

Founded in 2010 and publicly listed since 2014, Sage Therapeutics had set its sights on transforming treatment for brain disorders. Its lead program, Zurzuvae (zuranolone), co-developed with fellow Cambridge biotech Biogen, was heralded as a breakthrough for postpartum depression (PPD). In August 2023, the U.S. Food and Drug Administration (FDA) approved Zurzuvae for PPD, making it the first oral treatment approved for this indication. However, hopes for broader commercial success were dampened when the FDA declined to approve Zurzuvae for major depressive disorder (MDD), a much larger market. The narrow approval severely limited the drug’s revenue potential and sent Sage’s share price tumbling.

Compounding the challenge, in April 2024 Sage discontinued clinical development of its experimental Parkinson’s disease therapy after disappointing trial results. The company also rebuffed a $469 million acquisition bid from Biogen in January 2025, claiming it undervalued Sage’s potential—yet it soon accepted Supernus’s higher offer under mounting financial pressure.

Supernus Looks to Expand CNS Portfolio

For Supernus Pharmaceuticals, the acquisition opens the door to a differentiated product in Zurzuvae and strengthens its neurological and psychiatric therapeutic portfolio. Supernus, which boasts decades of experience in central nervous system disorders, markets established drugs for epilepsy, migraine, ADHD, and Parkinson’s disease. CEO Jack Khattar called the Sage deal “a major step in bolstering our future growth,” emphasizing the strategic fit between Zurzuvae’s novel depression treatment and Supernus’s CNS focus.

Supernus posted 2024 net product sales of roughly $725 million, driven by top-selling brands like Oxtellar XR (epilepsy) and Trokendi XR (migraine/epilepsy). By acquiring Sage, Supernus aims to diversify its revenue and deepen its presence in the psychiatric treatment market—a sector with significant unmet need but high clinical and payer barriers.

Industry Impact: Biotech Restructuring and M&A Surge

Sage’s fate is emblematic of wider noise in the biotech and pharmaceutical industries. From 2023 through 2025, the sector has seen an uptick in layoffs, restructurings, and M&A activity. A MassBio report states that over 3,000 Massachusetts biotech jobs were cut in 2023 alone, with R&D-heavy companies disproportionately affected.

The industry’s retrenchment stems from shifting capital markets, tougher regulatory environments, and high-profile setback with novel drug candidates. The recent rounds of layoffs at Sage, capped by this latest announcement, mirror layoffs across the region as biotechs adjust to investor caution and more demanding federal scrutiny over efficacy and safety.

Meanwhile, big pharma and midsize drugmakers, flush with cash from healthy product sales in chronic conditions and COVID-related revenue bump, are increasingly looking to acquire promising assets from smaller, cash-strapped biotechs. Notable recent deals include Eli Lilly’s $1.3 billion buyout of Verve Therapeutics and ongoing M&A in rare diseases and gene therapy.

Implications for Sage Employees and Cambridge Ecosystem

While some Sage employees may be offered opportunities within Supernus, the scale of workforce reduction suggests that many will face layoffs. This is a stark warning for Cambridge’s innovation economy—which has thrived on the region’s world-class academic centers and abundant venture funding, but now faces a harsher financial reality.

For the industry, the acquisition underscores that the road from discovery to commercial success in biotech is filled with risk—even for companies with FDA-approved products. While the consolidation may streamline drug development and open up new resources for products like Zurzuvae, it also highlights the increasingly tough decisions biotech leaders must make as markets and science evolve.

Looking Forward

The Sage-Supernus deal is expected to close in the third quarter of 2025, pending regulatory approvals. Industry observers will be watching to see if Supernus can capitalize on its expanded CNS pipeline and if the transaction signals a new chapter for post-pandemic biotech consolidation. For patients with postpartum depression, Supernus’s resources could help expand access to oral therapies like Zurzuvae, even as Sage’s once-ambitious research engine winds down.